On January 4, 2022 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, reported that it will participate in the following conferences in January 2022 (Press release, Vivoryon Therapeutics, JAN 4, 2022, View Source [SID1234598012]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Bioconnect Conference

Date: January 10 − 13, 2022

Venue: virtual

Presenter: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics

A webcast of the presentation will be available from Monday, January 10, 2022, at 7:00 am ET (1:00 pm CET) via the "Presentations & Webcasts" page in the Investor Relations section on the Company’s website at www.vivoryon.com and will be archived on the Company’s website for 30 days following the conference.

J.P. Morgan Health Care Conference

Date: January 10 − 13, 2022

Venue: virtual

Participants: Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO of Vivoryon Therapeutics

On January 4, 2022 Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, reported a strategic partnership to further understanding of the human proteome (Press release, Abcam, JAN 4, 2022, View Source [SID1234598011]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The field of proteomic analysis is in the spotlight. Its advance not only enhances the understanding of fundamental biology, but also sheds light on the status of human health and disease. A deeper understanding of the proteome is set to play a crucial role in enabling the next wave of innovations in research, diagnostics and therapeutics. Powering this effort requires new technology platforms that are able to address the two essential goals in proteomic analysis, namely the ability to go as deeply as possible to detect very low abundance proteins and the ability to profile thousands of proteins in a single sample.

"Alamar is working to enable the early detection of cancer and other diseases by simultaneous measurement of hundreds to thousands of targets, even those present in minute amounts. We are very happy to partner with Abcam to access their extensive portfolio of recombinant monoclonal antibody pairs, which will accelerate our ability to bring our proteomic discovery tools to researchers"
Dr. Yuling Luo
Founder & CEO of Alamar

"We are excited to be partnering with Alamar as they develop an automated proteomics platform that has the potential to offer unprecedented combination of sensitivity, plex-level and dynamic range. The NULISA technology platform will provide an important tool for life science research, pharmaceutical development and diagnostics, enhancing understanding of the circulating proteome and supporting low abundance biomarker discovery. Such capability will be critical for the discovery and measurement of many proteins in human plasma and other samples that are currently undetectable."
Dr Emma Sceats
SVP Sales, Service and Business Development at Abcam

Abcam’s portfolio of over 1,300 fit-for-purpose recombinant antibody pairs is actively curated to ensure that it is representative of the key disease areas of interest. Designed to enhance biomarker discovery and support deeper understanding of the circulating proteome, the portfolio has been pre-validated specifically for multiplex applications.

On January 3, 2022 Panolos Bioscience reported on the 27th that it has signed a joint research and development contract with AimedBio, a brain disease treatment development company, for brain tumor new drug ”PB101” (Press release, Panolos Bioscience, JAN 3, 2022, View Source [SID1234633688]). Panolos is a new drug development biotech based on a multifunctional recombinant protein platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PB101 is currently in the preclinical toxicity test phase, and is aiming to apply for a phase 1 clinical trial protocol (IND) next year. In addition, Panolos has signed a consignment development (CDO) contract with Samsung Biologics for PB101.

Aimed Bio plans to cooperate with Panolos by participating in the establishment of strategies for preclinical and clinical development of PB101.

Specifically, in this joint study, AimedBio selected indications for clinical development of PB101 through big data-based biomarker selection and PDC/PDX (patient derived cell/patient derived xenograft) experiments, as well as clinical trials such as non-clinical research and development of combined administration. We plan to collaborate to increase the test success rate.

PB101 is VEGF-Grab, a fusion protein in which IgG1 Fc is coupled with glycosylated VEGF1 receptor (VEGFR1). According to Panolos, PB101 can suppress all angiogenic factors such as VEGF-A, VEGF-B, and placental growth factor (PlGF) that are overexpressed in the tumor microenvironment.

Avastin, a VEGF drug currently on the market, inhibits VEGF-A, while Eylia mainly inhibits VEGF-A/B with VEGF-Trap. In addition, PIGF expression increases with the administration of existing VEGF drugs, and PIGF overexpression is associated with poor prognosis of patients, so higher anticancer efficacy is expected as PIGF is inhibited.

In addition, as a result of recent preclinical studies, it was confirmed that Panolos is superior to existing VEGF drugs in terms of cancer cell growth inhibition, blood vessel normalization, and tumor microenvironment control. The company expects additional efficacy when administered in combination with immune checkpoint inhibitors.

Nam Do-hyun, CEO of AimdBio, said, "Intractable solid cancers, including brain tumors, do not have treatments and have high unmet needs. Selecting the correct indication and establishing a clinical development strategy accordingly determines the success of new drug development." Through collaboration with transplant models and clinical experts, we want to make PB101 a success story for the solid cancer market where there is no current treatment."

Meanwhile, Panolos is building a follow-up bi-antibody/multi-antibody project that attaches additional tumor targeting and immune activating factors based on PB101 ”αARTTM”, which inhibits multiple angiogenesis factor targets.

On January 3, 2022 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, reported that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 10:30 a.m. EST (Press release, C4 Therapeutics, JAN 3, 2022, View Source [SID1234609971]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.

On January 3, 2022 Nordic Pharma reported that on 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion Teysuno: Pending EC decision | European Medicines Agency (europa.eu)] recommending the use of Teysuno (tegafur/gimeracil/oteracil) for the treatment of patients with metastatic colorectal cancer who cannot continue fluoropyrimidine treatment due to specific toxicities: hand-foot syndrome and cardiotoxicity (Press release, Nordic Pharma, JAN 3, 2022, View Source [SID1234607538]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CHMP supports including patients who developed these toxicities in the adjuvant setting in addition to metastatic patients.

Teysuno is an oral fluoropyrimidine with similar efficacy, but improved safety profile compared with other fluoropyrimidines.

Based on this positive opinion Teysuno will be indicated in adults:

for the treatment of advanced gastric cancer when given in combination with cisplatin (current indication).
as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting (pending European Committee decision).

New fluoropyrimidine for patients with metastatic colorectal cancer

nordic_pharma_thumbnail_green_colon

In metastatic colorectal cancer the typical first-line chemotherapy contains of a fluoropyrimidine used in various combinations.

Jean-Michel Quinot, CEO of Nordic Pharma stated: "This is important news for patients with metastatic colorectal cancer. Teysuno offers those patients suffering from toxicities that can cause discontinuation of therapy an alternative fluoropyrimidine therapy which allows them to continue systemic treatment that is known to significantly prolong survival. By being able to meet this medical need, we hope to contribute to improving the lives of these patients. We want to particularly thank medical oncologists and patients in different European countries who contributed to collecting crucial clinical data for this new indication."

Iris van Lakerveld, Global Oncology Lead added: "Fluoropyrimidines are, and will continue to be, the cornerstone of chemotherapy treatment in metastatic colorectal cancer. A significant group of patients can now be offered an alternative, in the event that chemotherapy needs to be delayed, the dose reduced or fully stopped because of hand-foot syndrome or cardiotoxicity. Side effects with chemotherapy are inevitable. With Teysuno, physicians and patients will have an additional therapy when needed, allowing optimal benefit of fluoropyrimidine treatment.

Nordic Pharma has licenced Teysuno from Taiho Pharmaceutical Co., Ltd. in Japan. In Japan, the product is known as TS-1 and is approved for various solid tumours, including gastric and colorectal cancer. Since 2011 Teysuno has been on the European market in 17 countries. In total, the product is marketed in over 30 countries worldwide.

This positive CHMP opinion is a first step in providing patients with metastatic colorectal cancer access to Teysuno. EMA’s opinion needs to be adopted by the European Commission, and subsequently country-specific reimbursement applications will be done at the level of each Member State to ensure this access.